Suppr超能文献

万古霉素诱导的肠道微生物组改变对健康男性受试者中美比达药效动力学的影响。

Effects of vancomycin-induced gut microbiome alteration on the pharmacodynamics of metformin in healthy male subjects.

机构信息

Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South Korea.

Department of Biomedical Sciences, Seoul National University College of Medicine and Hospital, Seoul, South Korea.

出版信息

Clin Transl Sci. 2021 Sep;14(5):1955-1966. doi: 10.1111/cts.13051. Epub 2021 May 31.

Abstract

Metformin is a major treatment for type 2 diabetes. This study was conducted to investigate the impact of gut microbiome dysbiosis on the pharmacokinetics and antihyperglycemic effects of metformin. Healthy adult males aged 19-45 years with no defecation abnormalities were recruited for this 4-period clinical study: baseline; post-metformin (i.e., multiple oral doses of 1000 mg metformin on days 1-4); post-vancomycin (i.e., multiple oral doses of 500 mg vancomycin on days 11-17 inducing gut microbiome changes); and post-metformin + vancomycin (i.e., multiple oral doses of 1000 mg metformin on days 16-19). In each period, serum glucose and insulin concentrations following an oral glucose tolerance test, fecal samples for gut microbiome composition, and safety data were obtained. Following metformin dosing, plasma and urine samples for pharmacokinetics were collected. Nine subjects completed the study. The pharmacokinetics of metformin remained unchanged, and the antihyperglycemic effect was significantly decreased after vancomycin administration (p value = 0.039), demonstrating the weak relationship between the pharmacokinetics and pharmacodynamics of metformin. Relative abundances of some genus were changed after vancomycin administration, and tended to correlate with the antihyperglycemic effects of metformin (p value = 0.062 for Erysipelatoclostridium; p value = 0.039 for Enterobacter; and p value = 0.086 for Faecalibacterium). Adverse events occurred in all subjects and were resolved without sequelae. In conclusion, a decrease in the antihyperglycemic effect of metformin was observed after concomitant administration with vancomycin, without changes in metformin pharmacokinetics. The antihyperglycemic effect was tended to correlate with the relative abundance of several genus, suggesting that the effect of metformin is partly attributable to the gut microbiome (ClinicalTrials.gov, NCT03809260).

摘要

二甲双胍是治疗 2 型糖尿病的主要药物。本研究旨在探讨肠道微生物组失调对二甲双胍药代动力学和降血糖作用的影响。本 4 期临床研究纳入了 19-45 岁、无排便异常的健康成年男性:基线期;二甲双胍后(即第 1-4 天多次口服 1000mg 二甲双胍);万古霉素后(即第 11-17 天多次口服 500mg 万古霉素诱导肠道微生物组变化);以及二甲双胍+万古霉素后(即第 16-19 天多次口服 1000mg 二甲双胍)。在每个时期,均进行口服葡萄糖耐量试验后采集血清葡萄糖和胰岛素浓度、粪便样本进行肠道微生物组组成检测以及获取安全性数据。在给予二甲双胍后采集药代动力学的血浆和尿液样本。9 名受试者完成了研究。万古霉素给药后,二甲双胍的药代动力学保持不变,降血糖作用明显降低(p 值=0.039),表明二甲双胍的药代动力学与药效学之间的关系较弱。万古霉素给药后一些属的相对丰度发生变化,且与二甲双胍的降血糖作用呈趋势相关(Erysipelatoclostridium 的 p 值=0.062;Enterobacter 的 p 值=0.039;Faecalibacterium 的 p 值=0.086)。所有受试者均发生不良事件,且均无后遗症解决。结论,与万古霉素同时给药后观察到二甲双胍的降血糖作用降低,而二甲双胍的药代动力学无变化。降血糖作用与几个属的相对丰度呈趋势相关,表明二甲双胍的作用部分归因于肠道微生物组(ClinicalTrials.gov,NCT03809260)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f85/8504811/1c883ceb9e13/CTS-14-1955-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验